CSL and more blue-chip ASX 200 bargains I’d buy before 2026

The ASX has spent most of 2025 swinging between optimism and anxiety, with inflation scares, rate hike speculation, and an AI-driven tech wobble keeping investors on edge.

But beneath is a rare opportunity to buy several high-quality ASX 200 blue chip shares at meaningful discounts.

Here are three bargains I’d be buying today.

CSL Ltd (ASX: CSL)

CSL is rarely cheap. For most of the last decade, the biotech giant traded at a premium thanks to its global leadership in plasma therapies, vaccines, and emerging specialty medicines. But 2025 has been an unusually bumpy year. Slower margin recovery at CSL Behring, uncertainty around the Seqirus spin-off, falling influenza vaccine rates, and concerns about potential US tariff impacts have pushed its share price down by over a third.

What hasn’t changed is the company’s long-term earnings power. Plasma collection volumes are rising, CSL’s R&D engine remains strong, and its therapy pipeline is expanding.

Trading on a valuation rarely seen for CSL, for long-term investors this could be a buying opportunity that doesn’t come around very often.

Macquarie Group Ltd (ASX: MQG)

Macquarie’s reputation as Australia’s financial powerhouse wasn’t built on smooth economic cycles. It was built through the company’s ability to generate growing profits whatever the market throws at it.

That’s why the current weakness in its share price, is looking like an opportunity. Macquarie has four engines: asset management, banking, commodities, and investment banking. When one slows, another usually accelerates. The company has also positioned itself for the next decade through investments in renewables, digital infrastructure, and global energy transition assets.

For investors with patience, buying Macquarie during periods of temporary earnings softness has historically paid off handsomely. I believe the same could happen for investors buying at today’s levels.

Woolworths Group Ltd (ASX: WOW)

Finally, I think Woolworths has quietly become one of the more attractive large-cap opportunities on the ASX after a challenging 12 months. The retailer has been under pressure due to consumers trading down, competition from Coles Group Ltd (ASX: COL), and higher operating costs. But these headwinds are cyclical, not structural.

Woolworths still owns one of the most defensible business models in the country. Food and essentials spending remain remarkably resilient, and it continues to grow its digital footprint, loyalty program, and supply-chain efficiencies.

So, with the share price sitting well below its 52-week high and margins set to recover as cost pressures ease, Woolworths could be a top blue chip pick in the current market.

The post CSL and more blue-chip ASX 200 bargains I’d buy before 2026 appeared first on The Motley Fool Australia.

More reading

• Macquarie names its top 4 ASX REITs to buy today
• Forget CSL shares, I’d buy this booming biotech stock instead
• With rising costs, are Woolworths shares still a good buy today?
• Seek shares tipped to storm 45% higher next year: Here’s why
• The ASX dividend stocks I’d trust to pay me through retirement

Motley Fool contributor James Mickleboro has positions in CSL and Woolworths Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group and Woolworths Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.